/A
Phase 1
- Conditions
- MedDRA version: 18.1 Level: LLT Classification code 10025170 Term: Lyme's disease System Organ Class: 100000004862
- Registration Number
- EUCTR2012-000313-37-FI
- Lead Sponsor
- TYKS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets are being investigated in EUCTR2012-000313-37-FI phase I Lyme's disease trial?
How does EUCTR2012-000313-37-FI compare to doxycycline in early-stage Borrelia burgdorferi infection management?
Which biomarkers correlate with treatment response in TYKS-sponsored phase I Lyme's disease interventional trials?
What adverse event profiles are reported in phase I trials targeting Borrelia burgdorferi outer surface proteins?
Are there combination therapies or competitor drugs for Lyme's disease with similar mechanisms to EUCTR2012-000313-37-FI?